<DOC>
	<DOCNO>NCT01712828</DOCNO>
	<brief_summary>To find blood level lenalidomide change drug prevents p-glycoprotein ( protein naturally present body help carry substance across cell membrane find many part body like intestine , liver , kidney ) work ( call P-gp inhibitor ) take together lenalidomide . The study also try find blood level temsirolimus change subject take lenalidomide together temsirolimus .</brief_summary>
	<brief_title>Effect P-glycoprotein Inhibition Lenalidomide Pharmacokinetics Healthy Males</brief_title>
	<detailed_description>This single-center , open label , 2-part study . Part 1 two-period , fixed-sequence crossover study lenalidomide alone Period 1 , follow lenalidomide combination quinidine Period 2 . Part 2 fixed-sequence , three-period , crossover study lenalidomide alone Period 1 , temsirolimus ( via direct intravenous infusion ) Period 2 , lenalidomide combination temsirolimus ( via direct intravenous infusion ) Period 3 . Diphenhydramine ( give via intravenous injection ) administer shortly temsirolimus order decrease chance allergic reaction temsirolimus . Part 1 Part 2 conduct time . Subjects participate either Part 1 Part 2 .</detailed_description>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<criteria>Must understand voluntarily sign write informed consent form prior studyrelated procedure perform . Must able communicate investigator , understand comply requirement study , agree adhere restriction examination schedule . Healthy male volunteer race 18 65 year age ( inclusive ) , good health determine physical exam . Agree use barrier contraception ( i.e. , condom make natural ( animal ) membrane [ e.g. , latex polyurethane condom acceptable ] ) engage sexual activity female childbearing potential study drug , least 90 day last dose study drug . Must body mass index 18 33 kg/m2 ( inclusive ) . Clinical laboratory test must within normal limit acceptable principal investigator . Must confirmation normal renal function ( defined estimate glomerular filtration rate &gt; 90 mL/min ) . Must afebrile , supine systolic blood pressure : 90 140 mmHg , supine diastolic blood pressure : 60 90 mmHg , pulse rate : 40 110 bpm . Must normal clinically acceptable 12lead electrocardiogram , QTcF ( Fridericia 's correction formula ) value ≤ 430 msec . Must refrain sperm donation entire duration study , least 90 day last dose study drug . History clinically significant relevant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychological , pulmonary , metabolic , endocrine , hematological , allergic disease , drug allergy , know hypersensitivity member class immunomodulatory drug ( IMiDs® ) , temosirolimus , sirolimus , polysorbate 80 , diphenhydramine , component ( excipients ) Torisel® , major disorder . Any condition place subject unacceptable risk participate study , confound ability interpret data study . Used prescribed systemic topical medication within 30 day first dose administration , unless Sponsor agreement obtain . Used nonprescribed systemic topical medication ( include vitamin/mineral supplement , herbal medicine ) within 14 day first dose administration , unless Sponsor agreement obtain . Used prescribed , nonprescribed , systemic topical medication CYP3A inhibitor inducer within 30 day first dose administration . ( refer ( http : //medicine.iupui.edu/clinpharm/ddis/p450_Table_Oct_11_2009.pdf ) Has surgical medical condition ( exclude appendectomy ) possibly affect drug absorption , distribution , metabolism excretion , e.g. , bariatric procedure . Donated blood plasma within 8 week first dose administration blood bank blood donation center . History drug abuse ( define current version Diagnostic Statistical Manual within 2 year dose , positive drug screen test reflect consumption illicit drug . History alcohol abuse ( define current version Diagnostic Statistical Manual ) within 2 year dose , positive alcohol screen . Known serum hepatitis know carrier hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCVAb ) , positive result test HIV antibodies Screening . Exposed investigational drug ( new chemical entity ) within 30 day precede first dose administration , 5 halflives investigational drug , know ( whichever longer ) . For Part 2 : total bilirubin ≥ 1.5x upper limit normal</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Lenalidomide ,</keyword>
	<keyword>Revlimid ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>healthy male subject</keyword>
</DOC>